selinexor

{
  "id": "MLC-T-ONC-007646",
  "term": "selinexor",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat adults with certain types of diffuse large B-cell lymphoma or multiple myeloma. It is used in patients whose cancer has already been treated with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor. Also called Xpovio.",
    "An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types."
  ],
  "synonyms": [
    "Xpovio",
    "CRM1 nuclear export inhibitor KPT-330",
    "selective inhibitor of nuclear export KPT-330",
    "SINE KPT-330"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/selinexor/"
}